Table of Contents

All the data and content are powered by ZXData, Learn more about ZXData

ZX Data private stock trade

Executive Summary

  • This quarter, reporting holders marked up their private portfolios by 16.9% ($ weighted) with an average mark-up of 5.9% (equal weighted).
  • Sentiment up:
  • Sentiment down:
  • In April, 27% of companies with ZX Index Values showed a difference of 10% or less compared to Fund Marks, and 38% of companies with ZX Index Values showed a difference of 20% or less compared to Fund Marks.

Heat Map: February 28th, 2025 Reporting Period

16.9%

Appreciation/Depreciation of All Reported Holdings1

5.9%

Average Mark-Up/Mark-Down Across All Reported Holdings2
X Holdings
129.3%
Scorpion Therapeutics
127.7%
SpaceX
58.2%
Anduril
55.6%
Anthropic
54.2%
Nuro
34.8%
Pine Labs
32.8%
Chime
32.0%
Tory Burch
25.8%
Lime
24.9%
Stripe
22.6%
Bombas
21.1%
Skyryse
21.1%
Retym
16.5%
Bytedance
16.2%
Relativity Space
16.1%
MNTN
15.5%
Tipalti
14.0%
Waymo
13.8%
Magic Leap
12.7%
VAST Data
10.8%
Omada Health
10.4%
Conformal Medical
10.1%
Insitro
9.6%
Caris
9.4%
Canva
9.3%
Candid
9.1%
Meesho
8.1%
Roofstock
6.7%
Figma
6.5%
Checkr
6.2%
Cleerly
5.6%
Ankyra
5.0%
Verily
5.0%
Algolia
4.2%
Discord
3.7%
Databricks
3.6%
Alif Semi
3.3%
Bolt
3.2%
Circle
3.2%
Moloco
3.2%
Aledade
2.9%
Asimov
2.8%
Ant Group
2.7%
Astranis
2.6%
Insightec
2.4%
Lenskart
2.4%
Applied Intuition
2.2%
Enevate
1.8%
Medical Micro
1.3%
ABL Space
1.1%
Blink Health
1.1%
Jumo
1.1%
SambaNova
0.9%
Asapp
0.6%
Epic Games
0.5%
Lightmatter
0.5%
Sila Nano
0.5%
PsiQuantum
0.3%
Tenstorrent
0.3%
Clio
0.1%
FogPharma
0.1%
Socure
0.1%
A24 Films
0.0%
Altos Labs
0.0%
Atom Tickets
0.0%
Bright Peak
0.0%
Cardurion
0.0%
Castle Creek
0.0%
City Therapeutics
0.0%
Color Genomics
0.0%
Cross River
0.0%
DataRobot
0.0%
Druva
0.0%
Einride
0.0%
Fabletics
0.0%
Faraday Pharma
0.0%
FLEXE
0.0%
Freenome
0.0%
Generate Bio
0.0%
GOAT
0.0%
Grammarly
0.0%
Gusto
0.0%
HaulHub
0.0%
Honor Tech
0.0%
Inscripta
0.0%
JUUL
0.0%
Kardium
0.0%
KoBold Metals
0.0%
Laronde
0.0%
LifeMine
0.0%
Quell
0.0%
Rappi
0.0%
Rapyd
0.0%
Resilience
0.0%
SecurityScorecard
0.0%
Skyhawk
0.0%
Snyk
0.0%
Sonoma Bio
0.0%
Tanium
0.0%
T-Knife
0.0%
Triveni Bio
0.0%
VideoAmp
0.0%
xAI
0.0%
Akeana
-0.1%
Deep Genomics
-0.1%
PrognomIQ
-0.1%
Unqork
-0.1%
Genesis Therapeutics
-0.2%
Evozyne
-0.3%
Cellanome
-0.5%
YuLife
-1.2%
Dataminr
-1.3%
AgomAb Therapeutics
-1.7%
Mirador Therapeutics
-2.7%
SiMa ai
-3.2%
Dragonfly Therapeutics
-3.5%
Saluda Medical
-3.5%
Redwood Materials
-4.2%
Adimab
-4.7%
Arctic Wolf
-4.7%
Goop
-4.7%
Element Bio
-5.4%
GupShup
-5.9%
goPuff
-6.3%
Zipline
-6.6%
Celonis
-7.1%
Klarna
-7.1%
Xsight Labs
-7.6%
Fanatics
-8.1%
Tarana
-8.2%
Thriveworks
-8.2%
Starling Bank
-8.3%
BETA Technologies
-8.9%
Liquid Death
-8.9%
EndeavorBio
-9.2%
Wugen
-9.3%
Menlo Micro
-9.4%
Farmers Business Network
-9.5%
Treeline Bio
-9.6%
Diamond Foundry
-9.7%
DNA Script
-10.1%
ElevateBio
-10.7%
Signifyd
-12.1%
Kartos Therapeutics
-12.4%
Locus Robotics
-12.4%
MasterClass
-12.4%
Odyssey Therapeutics
-17.3%
CelLink
-26.9%
Rad Power
-30.2%
Galvanize
-34.7%
Epirus
-42.7%
SalioGen
-90.9%
RefleXion Medical
-97.7%

1 Dollar-weighted return on all reported holdings
2 Equal-weighted mark-up or mark-down across all reported holdings

This quarter, reporting holders marked up their private portfolios by 16.9% ($ weighted) with an average mark-up of 5.9% (equal weighted).

X Holdings experienced the most significant mark-up, followed by Scorpion Therapeutics, SpaceX and Anthropic. Aerospace & Defense, SaaS and FinTech saw the largest mark-ups across sectors.

RefleXion Medical saw the largest mark-down, followed by SalioGen, Epirus and Galvanize. Among sectors, CleanTech, E-Commerce and Cybersecurity saw the largest mark-downs.

Comparison of ZX Index Value vs. Fund Marks

CompaniesRobustness Score3ZX Index Values4 vs. Fund Marks
Lime1+131.50%
GupShup1+83.90%
xAI7+78.80%
Sila Nano1+57.40%
Redwood Materials1+55.50%
Checkr1+52.80%
X Holdings1+50.60%
Tanium1+42.40%
Aledade1+35.00%
Blink Health2+34.90%
Signifyd1+32.40%
Anduril7+30.00%
VAST Data2+28.70%
DataRobot2+26.80%
Gusto6+23.30%
Stripe8+12.60%
SpaceX8+10.20%
Figma6+8.30%
Anthropic7+8.00%
Klarna1+6.40%
Cross River1+5.90%
Databricks4+3.00%
Dataminr2+1.50%
Meesho2+0.70%
Epirus1-0.60%
JUUL1-1.00%
Circle7-2.90%
Canva2-4.00%
Lightmatter2-4.30%
Discord8-4.80%
Tenstorrent1-9.50%
Bolt2-10.00%
Revolut3-11.30%
Locus Robotics1-14.60%
Liquid Death2-19.00%
Chime2-19.30%
Omada Health1-21.80%
Freenome1-22.00%
Zipline3-24.90%
Celonis1-25.50%
PsiQuantum2-27.10%
Grammarly1-29.40%
Bytedance7-30.80%
Arctic Wolf1-30.90%
KoBold Metals1-31.00%
Rapyd2-31.20%
Epic Games2-32.50%
SambaNova3-34.20%
Fanatics6-36.20%
Algolia1-38.70%
VideoAmp1-39.60%
Snyk2-47.00%
MNTN1-53.20%
Celestial AI1-54.30%
Oura Health2-69.90%
Altos Labs1-71.90%

3 ZXData Robustness Score is an internally developed metric to assign confidence levels to the underlying data used in constructing ZXData output metrics. The ZXData Robustness Score is calculated on a scale of 1 to 10 for each company, based on the number of executed trades, number of buy and sell orders submitted to ZX and skewness of the order book.
4 ZX Index Value is an internally developed metric that reflects secondary values for private companies using an algorithmic approach based on the values sourced from ZX and ZXData partners. The algorithm used to calculate ZX Index Values incorporates both executed transaction values and bid and ask pricing.

In April, 27% of companies with ZX Index Values showed a difference of 10% or less compared to Fund Marks, and 38% of companies with ZX Index Values showed a difference of 20% or less compared to Fund Marks. Among the companies, Lime, GupShup, xAI and Sila Nano had the highest positive variance in reported marks versus ZX Index Values. Altos Labs, Oura Health, Celestial AI and MNTN had the highest negative variance in reported marks versus ZX Index Values.

Highest Variance in Reported Marks
CompanyNormalized Std Dev5$ Weighted AvgMaxMin
Rad Power.61$0.39$0.67$0.14
Nuro.39$6.49$10.94$4.68
DNA Script.37$199.07$233.19$36.33
Grammarly.28$18.42$27.80$15.51
MasterClass.24$3.83$4.72$2.86

5 Normalized Standard Deviation is used to express the measure of spread across reported marks and allows for comparison between companies independent of their price per share based on a dollar-weighted average.

This period, Rad Power ($0.39 - $0.67) saw the highest share price variance across funds followed by Nuro ($6.49 - $10.94) and DNA Script ($36.33 - $233.19).

Positive Trend Reversal6 (# = consecutive prior qtrs marked down or flat)
Negative Trend Reversal7 (# = consecutive prior qtrs marked up or flat)
Positive Trend Reversal6 (# = consecutive prior qtrs marked down or flat)
Checkr, Waymo
13
Nuro
12
JUUL
7
Enevate
5
Negative Trend Reversal7 (# = consecutive prior qtrs marked up or flat)
Klarna
8
PsiQuantum
6
Odyssey Therapeutics
4
Databricks
5

6 Positive Trend Reversal reflects an individual holding marked up after consecutive quarterly periods marked down or flat
7 Negative Trend Reversal reflects an individual holding marked down after consecutive quarterly periods marked up or flat

Checkr and Waymo saw their first positive reversals in thirteen quarters while Nuro saw its first positive reversal in twelve quarters. Klarna saw its first negative reversal in eight quarters, while PsiQuantum saw its first negative reversal in six quarters.

Disclaimer

This report is based on data reported by 300+ funds and $60+ billion of value. Many holders of private company shares do not report their holding values and are thus not included in this report’s dataset. Further, many venture-backed private companies are not held by any reporting funds and are thus not included in this report. As such, this report should not be construed as providing a complete picture of shareholder sentiment or venture-backed private company performance. This report does not constitute investment advice or a "research report" as defined by FINRA Rules.

The “ZX Index Value” is derived by applying proprietary weightings to the order flow data collected for the stated period (both bids and asks), based on the order type (firm order or indication of interest) and whether the order has been executed, with greater weight given to more recent orders.

Zanbato, Inc. (“Zanbato”) prepares and disseminates market information about venture-backed private company securities, and the current bids and offers for those securities listed on the ATS operated by Zanbato (“ZX”). The information provided in this report has been prepared by sales, trading, or other non-research functions. Pricing indications and macro commentary are provided for information purposes only. This report is not intended to assess the individual merits of a particular investment or strategy, does not constitute a recommendation to buy or sell any financial instrument or to participate in any trading strategy and should not be construed as such. This report does not constitute investment advice. Certain information in this report has been obtained from third party sources and, while such information is believed by Zanbato to be reliable, it has not been independently verified by Zanbato and Zanbato shall not be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with any use of, or reliance on, such third party information. Furthermore, the information contained in this report may not be current due to, among other things, changes in the financial markets or economic environment. Zanbato does not, and has no obligation to, update any such information contained in this report. Any prices or quotations contained herein are indicative only, do not represent firm quotes as to either price or size and should not be used for valuation purposes.

yukacon_arrow_up_right